Market Insights-arkiv - Page 2 of 6 - Biosector Ltd.

by Stefan Sandström

Takeda’s Savings Spree: What the Restructuring Really Means Now

Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]

0

by Stefan Sandström

Takeda’s JPY 200 Billion Pivot: Welcome to Takeda’s New Launch Machine

The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]

1

by Stefan Sandström

Where the Organoid Field Stands Today

0

by Stefan Sandström

Infographic: Why CNS is the next Battleground for Organoids

0

Business executive overlooking Japan’s pharmaceutical opportunity, with Mount Fuji, Tokyo skyline, Shinkansen, laboratory scientists, DNA helix, medicine vials, and an upward growth graph.

by Stefan Sandström

Catching Pharmaceutical Opportunities in Japan’s Reinvented Pharmaceutical Arena

For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]

0

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Illustration of the supply chain for targeted alpha therapy in Japan using Astatine-211. The graphic shows domestic cyclotron production, GMP radiochemistry and automated purification, a national site network strategy, time-critical logistics across Japan due to the 7.2-hour half-life, and outpatient administration of the radiopharmaceutical.

by Stefan Sandström

Targeted Alpha Therapy in Japan: why Domestic ²¹¹At Supply Matters for Scale

Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]

0

Abstract wide illustration showing Japan drug pricing from listing to post-launch revisions, using blue shapes on a sand background with red trigger markers.

by Stefan Sandström

December 15, 2025

Japan FY2026 Drug Pricing Reform Draft: What Changes at Listing, What Tightens After Launch

On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline […]

0

Photorealistic scene of a consultant in a Tokyo meeting room connecting a foreign company with Japanese pharma executives.

by Stefan Sandström

December 11, 2025

Why Japanese Targets Like You, Listen to You – and Still You Don’t Succeed

You fly in, you present, you charm the room. Heads nod. The technical team likes your […]

0

Abstract flat illustration of Japanese blockbuster drugs falling off a 2026 PMP price cliff with coloured bars and icons for key therapy areas.

by Stefan Sandström

December 8, 2025

Japan’s FY2026 Drug Price Revision: PMP Return and the End of the Long-Tail Blockbuster

Japan’s pharmaceutical market is about to run a high-stakes experiment in how hard a mature health […]

0